## What Is Claimed Is:

- An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
  - (a) a nucleotide sequence encoding a polypeptide comprising amino acids 1 to 271 in Figures 1A-B;
  - (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about 30 to about 271 in Figures 1A-B;
  - (c) a nucleotide sequence encoding a polypeptide comprising amino acids
    Asp-30 to Glu-57 in Figures 1A-B;
    - (d) a nucleotide sequence encoding amino acids 1 to 194 of Figure 2;
  - (e) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in clone HCFMV39 (ATCC Deposit Number 97974 or 209080) or HMUCL01 (ATCC Deposit Number PTA-2259);
  - (f) a nucleotide sequence encoding the mature TR21 or TR22 polypeptide having the amino acid sequence encoded by the cDNA clone contained in clone HCFMV39 or HMUCL01, respectively:
  - (g) a nucleotide sequence encoding the extracellular domain of the TR21 or TR22 polypeptide having the amino acid sequence encoded by the cDNA clone contained in clone HCFMV39 or HMUCL01, respectively;
  - (h) a nucleotide sequence encoding the transmembrane domain of the TR21 or TR22 polypeptide having the amino acid sequence encoded by the cDNA clone contained in clone HCFMV39 or HMUCL01, respectively;
  - (i) a nucleotide sequence encoding the intracellular domain of the TR21 or TR22 polypeptide having the amino acid sequence encoded by the cDNA clone contained in clone HCFMV39 or HMUCL01, respectively;
  - a nucleotide sequence encoding the TR21 or TR22 receptor extracellular and intracellular domains with all or part of the transmembrane domain deleted;
     and

- (k) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j).
- 2. The nucleic acid molecule of claim 1, wherein said polynucleotide comprises the nucleotide sequence in Figure 1.
- The nucleic acid molecule of claim 1, wherein said polynucleotide comprises the nucleotide sequence in Figure 2.
- The nucleic acid molecule of claim 1, wherein said polynucleotide has the complete nucleotide sequence of the cDNA clone contained in HCFMV39.
- The nucleic acid molecule of claim 1, wherein said polynucleotide has the complete nucleotide sequence of the cDNA clone contained in HMUCL01.
- 6. An isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (j) of claim 1, wherein said polynucleotide does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.
- An isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of a TR21 receptor having an amino acid sequence in Figures 1A-B or encoded by clone HCFMV39.
- An isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of a TR22 receptor having an amino acid sequence in Figure 2 or encoded by clone HMUCL01.

- 9. An isolated nucleic acid molecule comprising encoding a polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
  - (a) the amino acid sequence of Figures 1A-B;
  - (b) the amino acid sequence encoded by the cDNA of clone HCFMV39;
  - (c) the amino acid sequence of Figure 2; and
  - (d) the amino acid sequence encoded by the cDNA of clone HMUCL01.
  - 10. An isolated polypeptide encoded by the nucleic acid molecule of claim 9.
- 11. An isolated polypeptide comprising an antigenic epitope contained in a polypeptide having an amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of Figures 1A-B;
  - (b) the amino acid sequence encoded by the cDNA of clone HCFMV39;
  - (c) the amino acid sequence of Figure 2; and
  - (d) the amino acid sequence encoded by the cDNA of clone HMUCL01.
  - 12. An isolated antibody that binds specifically to the polypeptide of claim 10.
  - 13. An isolated antibody that binds specifically to the polypeptide of claim 11.
- 14. A method of treating an immune disorder comprising administering an effective amount of the polypeptide as claimed in claim 10, or an agonist thereof to a patient in need thereof.
- 15. A method of treating an immune disorder comprising administering an effective amount of the antibody as claimed in claim 12.
- 16. An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide wherein, except for one to ten conservative amino acid substitutions, said polypeptide has an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of Figures 1A-B;
- (b) the amino acid sequence encoded by the cDNA of clone HCFMV39;
- (c) the amino acid sequence of Figure 2; and
- (d) the amino acid sequence encoded by the cDNA of clone HMUCL01.
- 17. An isolated polypeptide wherein, except for one to ten conservative amino acid substitutions, said polypeptide has a sequence selected from the group consisting of:
  - (a) the amino acid sequence of Figures 1A-B;
  - (b) the amino acid sequence encoded by the cDNA of clone HCFMV39;
  - (c) the amino acid sequence of Figure 2; and
  - (d) the amino acid sequence encoded by the cDNA of clone HMUCL01.
  - 18. The antibody of claim 12 that is an scFv fragment.
  - 19. The antibody of claim 12 that is an Fab fragment.
- 20. A method of inhibiting proliferation of a cell expressing TR21 or TR22, comprising contacting the cell with an antagonistic antibody or antibody fragment, or other antagonist of TR21 or TR22.
- 21. A method of enhancing proliferation of a cell expressing TR21 or TR22, comprising contacting the cell with an agonistic antibody or antibody fragment, or other agonist of TR21 or TR22.